A Phase 1b/2, Open-Label, Master Protocol Study of BTK- Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

  • Tatarczuch, Maciej (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date10/04/25 → 9/04/27

Keywords

  • Clinical Trials
  • BGB-16673-104

Clinical Trial Phase

  • Phase I